{"id":"NCT01976338","sponsor":"Novartis Pharmaceuticals","briefTitle":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)","officialTitle":"A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-12","primaryCompletion":"2016-03-28","completion":"2016-03-28","firstPosted":"2013-11-05","resultsPosted":"2017-05-08","lastUpdate":"2017-05-08"},"enrollment":283,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Edema Secondary to Branch Retinal Vein Occlusion"],"interventions":[{"type":"DRUG","name":"Ranibizumab 0.5 mg","otherNames":[]},{"type":"OTHER","name":"Sham injection","otherNames":["Sham"]}],"arms":[{"label":"Ranibizumab 0.5 mg","type":"EXPERIMENTAL"},{"label":"Sham injection","type":"SHAM_COMPARATOR"}],"summary":"Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO","primaryOutcome":{"measure":"Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6","timeFrame":"Baseline to Month 1 through Month 6","effectByArm":[{"arm":"Ranibizumab 0.5 mg","deltaMin":12.5,"sd":8.34},{"arm":"Sham Injection","deltaMin":5,"sd":9.18}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":8},"locations":{"siteCount":33,"countries":["China","Hong Kong","Indonesia","Philippines","Taiwan","Vietnam"]},"refs":{"pmids":["31902472"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":190},"commonTop":["Nasopharyngitis","Hypertension","Conjunctival haemorrhage","Cough","Headache"]}}